Health Insurance published this Thursday, November 14, the list of reimbursed medications most consumed in France.
“The right treatment is not necessarily medication.” Health Insurance published this Thursday, in a document, the list of reimbursed medications most consumed in France during the year 2023.
It must be said that the French are among the largest consumers of medicines in the world. In France, total consumption reached 35.2 billion euros in 2023, according to the health organization.
Doliprane and analgesics at the top of the ranking
Unsurprisingly, Doliprane, heart of a political-economic battle, comes out on top. Between June 2023 and June 2024, the French's favorite painkiller was prescribed to some 36 million patients, or more than 60% of policyholders covered by the health organization. With 308.2 million boxes delivered to pharmacies, the success of the iconic little yellow box is clear.
Secondly, we find a drug, which is also from the analgesic family: Dafalgan with 71.6 million boxes sold to 6.8 million patients. Note that another painkiller, Efferalgan, is 5th in the ranking, with 23.9 million boxes sold to 2.6 million French people.
Levothyrox, 3rd best-selling drug in France
The podium is completed by Levothyrox. In total, 31.6 million boxes of this drug, used to regulate thyroid glands, were sold in France in 2023.
4th place is occupied by Kardegic, an antithrombotic of which 26.7 million boxes have been sold in France in 2023. Further down the rankings include Zymad, a vitamin D tablet (6th, 13.6 million boxes), Ventolin (12th, 12.8 million boxes), and Spasfon (19th, 9.7 million boxes).
